Effect of exenatide on β cell function after islet transplantation in type 1 diabetes

Transplantation

Volumn 83, Issue 1, 2007, Pages 24-28

  Ghofaili, Khalid Al ^a   Fung, Michelle ^a   Ao, Ziliang ^a   Meloche, Mark ^a   Shapiro, R Jean ^a   Warnock, Garth L ^a   Elahi, Dariush ^b   Meneilly, Graydon S ^a,c   Thompson, David M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Exenatide; GLP 1; Islet transplantation; Type 1 diabetes

Indexed keywords

C PEPTIDE; EXENDIN 4; GLUCOSE; INSULIN; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLYCEMIC CONTROL; GRAFT REJECTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; NAUSEA; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 33846252337     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000251379.46596.2d     Document Type: Article

References (19)

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pancreas and Islet Transplantation. Canadian Journal of Diabetes 2003; 27(suppl 2): S55.
2. Ryan EA, Paty BW, Senoir PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
3. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005; 5: 2037.
4. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830.
5. Fung M, Thompson DM, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS. Effect of glucagon-like peptide-1 (7-37) on beta cell function after islet transplantation in type 1 diabetes. Diab Res Clin Pract 2006; 74: 189.
6. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092.
7. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083.
8. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation and apoptosis. Molecular Endocrinology 2005; 17: 161.
9. Warnock GL, Meloche RM, Thompson D, et al. Improved human pancreatic islet isolation for a prospective cohort study of islet transplantation vs best medical therapy in type 1 diabetes mellitus. Archives of Surgery 2005; 140: 735.
10. Andres R, Swerdloff R, Pozefsky T, Coleman D. Manual feedback technique for control of glucose concentration. In Skeggs LT Jr Ed. Automation in Analytic Chemistry 1996; 486.
11. McGuire EAH, Helderman JH, Tobin JD, Andres JD, Berman M. Arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol 1976; 41: 565.
12. Meneilly GS, McIntosh CHS, Pederson RA, et al. Effect of Glucagon-like peptide-1 (7-37) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care 2003; 26: 837.
13. Rickels MR, Schutta MH, Markmann JF, Barker CF, Naji A, Teff KL. B-cell function following human islet transplantation for type 1 diabetes. Diabetes 2005; 54: 100.
14. Holz GG. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic β-cells. Horm Metab Res 2004; 36: 787.
15. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51(suppl 3): S368.
16. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function. Diabetes 2004; 53: 250.
17. Deacon CF. What do we know about the secretion and degradation of incretin hormones. Regul Pept 2005; 128: 117.
18. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370.
19. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149.